TLR4 and neoplasm: It is recently suggested that blocking TLR4 could significantly improve response to PTX therapy [13] by regulating both local and systemic inflammatory pathways that promote malignant progression, tumor recurrence and the establishment of metastatic lesions, either during chemotherapy or after it is completed [42].